90 related articles for article (PubMed ID: 15562384)
1. Effect of repaglinide and gliclazide on postprandial control of endogenous glucose production.
Singhal P; Caumo A; Cobelli C; Taylor R
Metabolism; 2005 Jan; 54(1):79-84. PubMed ID: 15562384
[TBL] [Abstract][Full Text] [Related]
2. Effect of repaglinide and gliclazide on glycaemic control, early-phase insulin secretion and lipid profiles in.
Zhang H; Bu P; Xie YH; Luo J; Lei MX; Mo ZH; Liao EY
Chin Med J (Engl); 2011 Jan; 124(2):172-6. PubMed ID: 21362360
[TBL] [Abstract][Full Text] [Related]
3. Comparison of repaglinide vs. gliclazide in combination with bedtime NPH insulin in patients with Type 2 diabetes inadequately controlled with oral hypoglycaemic agents.
Furlong NJ; Hulme SA; O'Brien SV; Hardy KJ
Diabet Med; 2003 Nov; 20(11):935-41. PubMed ID: 14632720
[TBL] [Abstract][Full Text] [Related]
4. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815
[TBL] [Abstract][Full Text] [Related]
5. Regulation of endogenous glucose production after a mixed meal in type 2 diabetes.
Singhal P; Caumo A; Carey PE; Cobelli C; Taylor R
Am J Physiol Endocrinol Metab; 2002 Aug; 283(2):E275-83. PubMed ID: 12110532
[TBL] [Abstract][Full Text] [Related]
6. Effect of repaglinide versus glyburide on postprandial glucose and insulin values in elderly patients with type 2 diabetes.
Meneilly GS
Diabetes Technol Ther; 2011 Jan; 13(1):63-5. PubMed ID: 21175273
[TBL] [Abstract][Full Text] [Related]
7. Repaglinide has more beneficial effect on cardiovascular risk factors than glimepiride: data from meal-test study.
Rizzo MR; Barbieri M; Grella R; Passariello N; Paolisso G
Diabetes Metab; 2005 Jun; 31(3 Pt 1):255-60. PubMed ID: 16142016
[TBL] [Abstract][Full Text] [Related]
8. Comparison of insulin sensitivity, glucose sensitivity, and first phase insulin secretion in patients treated with repaglinide or gliclazide.
Wu CZ; Pei D; Hsieh AT; Wang K; Lin JD; Lee LH; Chu YM; Hsiao FC; Pei C; Hsia TL
Arch Pharm Res; 2010 Mar; 33(3):411-6. PubMed ID: 20361306
[TBL] [Abstract][Full Text] [Related]
9. Meal-induced platelet activation in Type 2 diabetes mellitus: effects of treatment with repaglinide and glibenclamide.
Yngen M; Ostenson CG; Hjemdahl P; Wallén NH
Diabet Med; 2006 Feb; 23(2):134-40. PubMed ID: 16433710
[TBL] [Abstract][Full Text] [Related]
10. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
11. Lack of effect of acute repaglinide administration on postprandial lipaemia in patients with type 2 diabetes mellitus.
Tentolouris N; Kolia M; Tselepis AD; Perea D; Kitsou E; Kyriaki D; Tambaki AP; Karabina SP; Sala C; Fragoulopoulos E; Katsilambros N
Exp Clin Endocrinol Diabetes; 2003 Sep; 111(6):370-3. PubMed ID: 14520605
[TBL] [Abstract][Full Text] [Related]
12. Compared to glibenclamide, repaglinide treatment results in a more rapid fall in glucose level and beta-cell secretion after glucose stimulation.
Abbink EJ; van der Wal PS; Sweep CG; Smits P; Tack CJ
Diabetes Metab Res Rev; 2004; 20(6):466-71. PubMed ID: 15386823
[TBL] [Abstract][Full Text] [Related]
13. Effects of short-term therapy with different insulin secretagogues on glucose metabolism, lipid parameters and oxidative stress in newly diagnosed Type 2 Diabetes Mellitus.
Li Y; Xu L; Shen J; Ran J; Zhang Y; Wang M; Yan L; Cheng H; Fu Z
Diabetes Res Clin Pract; 2010 Apr; 88(1):42-7. PubMed ID: 20060192
[TBL] [Abstract][Full Text] [Related]
14. Differential lipid profile and hormonal response in type 2 diabetes by exogenous insulin aspart versus the insulin secretagogue repaglinide, at the same glycemic control.
Chisalita SI; Lindström T; Eson Jennersjö P; Paulsson JF; Westermark GT; Olsson AG; Arnqvist HJ
Acta Diabetol; 2009 Mar; 46(1):35-42. PubMed ID: 18777156
[TBL] [Abstract][Full Text] [Related]
15. Repaglinide as monotherapy in Type 2 diabetes.
Gomis R
Exp Clin Endocrinol Diabetes; 1999; 107 Suppl 4():S133-5. PubMed ID: 10522838
[TBL] [Abstract][Full Text] [Related]
16. Flexible prandial glucose regulation with repaglinide in patients with type 2 diabetes.
Damsbo P; Marbury TC; Hatorp V; Clauson P; Müller PG
Diabetes Res Clin Pract; 1999 Aug; 45(1):31-9. PubMed ID: 10499883
[TBL] [Abstract][Full Text] [Related]
17. Defining the role of repaglinide in the management of type 2 diabetes mellitus: a review.
Johansen OE; Birkeland KI
Am J Cardiovasc Drugs; 2007; 7(5):319-35. PubMed ID: 17953471
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the effects of three insulinotropic drugs on plasma insulin levels after a standard meal.
Cozma LS; Luzio SD; Dunseath GJ; Langendorg KW; Pieber T; Owens DR
Diabetes Care; 2002 Aug; 25(8):1271-6. PubMed ID: 12145220
[TBL] [Abstract][Full Text] [Related]
19. Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes.
Owens DR; Luzio SD; Ismail I; Bayer T
Diabetes Care; 2000 Apr; 23(4):518-23. PubMed ID: 10857945
[TBL] [Abstract][Full Text] [Related]
20. Repaglinide: a new short-acting insulinotropic agent for the treatment of type 2 diabetes.
Owens DR
Eur J Clin Invest; 1999 Jun; 29 Suppl 2():30-7. PubMed ID: 10383608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
